| Autor: |
Gordon, Y. Jerold, Yates, Kathleen A., Mah, Francis S., Romanowski, Eric G. |
| Předmět: |
|
| Zdroj: |
Journal of Ocular Pharmacology & Therapeutics; Jun2003, Vol. 19 Issue 3, p233-245, 13p |
| Abstrakt: |
Purpose: Xalatan[sup ®] treatment has been reported both clinically and experimentally to promote recurrences of herpetic keratitis. Our goal was to determine the effects of topical Xalatan[sup ®] and its components on the recovery of ocular herpes simplex virus type 1 (HSV-1) in the Induced Reactivation (IR) and Spontaneous Shedding (SS) HSV-1/NZW rabbit latency models using virological outcome measures. Methods: HSV-1 latently-infected rabbits in both the IR and SS studies were divided into different topical treatment groups to evaluate commercial Xalatan[sup ®], its preservatives, and vehicle against appropriate negative and positive controls. In the IR Studies, 91 rabbits received intra-stromal injections of water in both eyes to promote ocular shedding of latent HSV-1. All eyes were then treated and cultured for 10 days. In the SS Studies, 65 rabbits were treated and cultured in both eyes for 30 days. Results: Dexamethasone, a positive control, promoted extensive ocular shedding of HSV-1 in both the IR and SS Models. In general, neither Xalatan[sup ®] nor its components demonstrated any adverse effects, but some experimental variation was noted. All groups demonstrated comparable recovery of latent HSV-1 from respective trigeminal ganglia. Conclusions: Our experimental studies support the world wide clinical epidemiological experience that commercial Xalatan[sup ®] does not appear to promote HSV-1 ocular shedding. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
